{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T17:55:55Z","timestamp":1774115755755,"version":"3.50.1"},"reference-count":213,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>Hypertension constitutes a major risk factor for heart failure with preserved ejection fraction (HFpEF). HFpEF is a prevalent clinical syndrome with increased cardiovascular morbidity and mortality. Specific guideline-directed medical therapy (GDMT) for HFpEF is not established due to lack of positive outcome data from randomized controlled trials (RCTs) and limitations of available studies. Although available evidence is limited, control of blood pressure (BP) is widely regarded as central to the prevention and clinical care in HFpEF. Thus, in current guidelines including the 2018 European Society of Cardiology (ESC) and European Society of Hypertension (ESH) Guidelines, blockade of the renin-angiotensin system (RAS) with either angiotensin-converting enzyme inhibitors or angiotensin receptor blockers provides the backbone of BP-lowering therapy in hypertensive patients. Although superiority of RAS blockers has not been clearly shown in dedicated RCTs designed for HFpEF, we propose that this core drug treatment strategy is also applicable for hypertensive patients with HFpEF with the addition of some modifications. The latter apply to the use of spironolactone apart from the treatment of resistant hypertension and the use of the angiotensin receptor neprilysin inhibitor. In addition, novel agents such as sodium-glucose co-transporter-2 inhibitors, currently already indicated for high-risk patients with diabetes to reduce heart failure hospitalizations, and finerenone represent promising therapies and results from ongoing RCTs are eagerly awaited. The development of an effective and practical classification of HFpEF phenotypes and GDMT through dedicated high-quality RCTs are major unmet needs in hypertension research and calls for action.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/hjh.0000000000002910","type":"journal-article","created":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T19:04:21Z","timestamp":1623179061000},"page":"1522-1545","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":71,"title":["Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension"],"prefix":"10.1097","volume":"39","author":[{"given":"Alexandros","family":"Kasiakogias","sequence":"first","affiliation":[{"name":"First Department of Cardiology, Hippokration Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece"}]},{"given":"Enrico Agabiti","family":"Rosei","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy"}]},{"given":"Miguel","family":"Camafort","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, ICMID, Hospital Cl\u00ednic, University of Barcelona, Barcelona, Spain"}]},{"given":"Georg","family":"Ehret","sequence":"additional","affiliation":[{"name":"Cardiology, Geneva University Hospitals, Geneva, Switzerland"}]},{"given":"Luca","family":"Faconti","sequence":"additional","affiliation":[{"name":"King's College London British Heart Foundation Centre, London, UK"}]},{"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, Centre d\u2019Investigations Cliniques Plurith\u00e9matique Inserm 1433"},{"name":"CHRU de Nancy, Inserm U1116"},{"name":"FCRIN INI-CRCT, Nancy, France"}]},{"given":"Jana","family":"Brguljan","sequence":"additional","affiliation":[{"name":"University Medical Centre Ljubljana, Hypertension Department, Medical University Ljubljana, Ljubljana, Slovenia"}]},{"given":"Andrzej","family":"Januszewicz","sequence":"additional","affiliation":[{"name":"Department of Hypertension, National Institute of Cardiology, Warsaw, Poland"}]},{"given":"Thomas","family":"Kahan","sequence":"additional","affiliation":[{"name":"Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Division of Cardiovascular Medicine, Stockholm, Sweden"}]},{"given":"Athanasios","family":"Manolis","sequence":"additional","affiliation":[{"name":"Cardiology Department, Asklepeion General Hospital, Athens, Greece"}]},{"given":"Konstantinos","family":"Tsioufis","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, Hippokration Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece"}]},{"given":"Thomas","family":"Weber","sequence":"additional","affiliation":[{"name":"Cardiology Department, Klinikum Wels-Grieskirchen, Wels, Austria"}]},{"given":"Thomas G.","family":"von Lueder","sequence":"additional","affiliation":[{"name":"\u00d8kern Heart Centre"}]},{"given":"Otto A.","family":"Smiseth","sequence":"additional","affiliation":[{"name":"Institute for Surgical Research and Department of Cardiology, Oslo University Hospital, Rikshospitalet, and University of Oslo"}]},{"given":"Kristian","family":"Wachtell","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital"}]},{"given":"Sverre E.","family":"Kjeldsen","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, Medical Faculty, University of Oslo, and Departments of Cardiology and Nephrology, Oslo University Hospital, Ullevaal, Oslo, Norway"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, Centre d\u2019Investigations Cliniques Plurith\u00e9matique Inserm 1433"},{"name":"CHRU de Nancy, Inserm U1116"},{"name":"FCRIN INI-CRCT, Nancy, France"}]},{"given":"Giuseppe","family":"Mancia","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Milano-Bicocca, Milan; Policlinico di Monza, Monza, Italy"}]},{"given":"Reinhold","family":"Kreutz","sequence":"additional","affiliation":[{"name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, Institut f\u00fcr Klinische Pharmakologie und Toxikologie, Berlin, Germany"}]}],"member":"276","published-online":{"date-parts":[[2021,6,16]]},"reference":[{"key":"R1-20250803","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","article-title":"2018\u200aESC\/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension","volume":"36","author":"Williams","year":"2018","journal-title":"J Hypertens"},{"key":"R2-20250803","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","article-title":"Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes","volume":"70","author":"Shah","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R3-20250803","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/eurjhf\/hfq121","article-title":"Epidemiology and clinical course of heart failure with preserved ejection fraction","volume":"13","author":"Lam","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"R4-20250803","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/ejhf.327","article-title":"Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response","volume":"17","author":"Kao","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"R5-20250803","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"R6-20250803","first-page":"e137","article-title":"2017\u200aACC\/AHA\/HFSA focused update of the 2013\u200aACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"136","author":"Yancy Clyde","year":"2017","journal-title":"Circulation"},{"key":"R7-20250803","doi-asserted-by":"crossref","first-page":"311","DOI":"10.7326\/0003-4819-147-5-200709040-00006","article-title":"Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients","volume":"147","author":"Okin","year":"2007","journal-title":"Ann Intern Med"},{"key":"R8-20250803","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"R9-20250803","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1093\/eurheartj\/ehy301","article-title":"Heart failure with preserved ejection fraction: from mechanisms to therapies","volume":"39","author":"Lam","year":"2018","journal-title":"Eur Heart J"},{"key":"R10-20250803","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2174\/1570161115666170414120532","article-title":"Hypertension and heart failure with preserved ejection fraction: connecting the dots","volume":"16","author":"Tsioufis","year":"2017","journal-title":"Curr Vasc Pharmacol"},{"key":"R11-20250803","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1161\/HYPERTENSIONAHA.119.14057","article-title":"Medical therapies for heart failure with preserved ejection fraction","volume":"75","author":"Kjeldsen Sverre","year":"2020","journal-title":"Hypertension"},{"key":"R12-20250803","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/HYPERTENSIONAHA.118.11065","article-title":"Role of renin-angiotensin-aldosterone system activation in promoting cardiovascular fibrosis and stiffness","volume":"72","author":"Jia","year":"2018","journal-title":"Hypertension"},{"key":"R13-20250803","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrcardio.2014.83","article-title":"The pathophysiology of heart failure with preserved ejection fraction","volume":"11","author":"Borlaug","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"R14-20250803","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1093\/eurheartj\/ehu204","article-title":"New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes","volume":"35","author":"Senni","year":"2014","journal-title":"Eur Heart J"},{"key":"R15-20250803","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/CIRCULATIONAHA.116.021884","article-title":"Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap","volume":"134","author":"Shah","year":"2016","journal-title":"Circulation"},{"key":"R16-20250803","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/ejhf.1621","article-title":"Phenomapping of patients with heart failure with preserved ejection fraction using machine learning-based unsupervised cluster analysis","volume":"22","author":"Segar","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"R17-20250803","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/ehf2.12660","article-title":"Variation in clinical and patient-reported outcomes among complex heart failure with preserved ejection fraction phenotypes","volume":"7","author":"Flint","year":"2020","journal-title":"ESC Heart Fail"},{"key":"R18-20250803","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.amjcard.2011.05.038","article-title":"Progression from concentric left ventricular hypertrophy and normal ejection fraction to left ventricular dysfunction","volume":"108","author":"Milani","year":"2011","journal-title":"Am J Cardiol"},{"key":"R19-20250803","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jchf.2017.04.012","article-title":"The transition from hypertension to heart failure: contemporary update","volume":"5","author":"Messerli","year":"2017","journal-title":"JACC Heart Fail"},{"key":"R20-20250803","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA\u2013PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur Heart J"},{"key":"R21-20250803","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1161\/CIRCULATIONAHA.119.041818","article-title":"Deliberating the diagnostic dilemma of heart failure with preserved ejection fraction","volume":"142","author":"Ho","year":"2020","journal-title":"Circulation"},{"key":"R22-20250803","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1161\/CIRCULATIONAHA.110.011031","article-title":"Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction","volume":"124","author":"Zile Michael","year":"2011","journal-title":"Circulation"},{"key":"R23-20250803","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1016\/j.jacc.2019.09.063","article-title":"Echocardiographic features of patients with heart failure and preserved left ventricular ejection fraction","volume":"74","author":"Shah","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R24-20250803","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.amjcard.2013.05.061","article-title":"Prevalence, clinical characteristics, and outcomes associated with eccentric versus concentric left ventricular hypertrophy in heart failure with preserved ejection fraction","volume":"112","author":"Katz","year":"2013","journal-title":"Am J Cardiol"},{"key":"R25-20250803","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIRCULATIONAHA.106.659763","article-title":"Cardiac structure and ventricular\u2013vascular function in persons with heart failure and preserved ejection fraction from olmsted county, minnesota","volume":"115","author":"Lam","year":"2007","journal-title":"Circulation"},{"key":"R26-20250803","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/0735-1097(92)90617-V","article-title":"Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension","volume":"19","author":"Ganau","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"R27-20250803","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1093\/eurheartj\/ehz158","article-title":"The continuous heart failure spectrum: moving beyond an ejection fraction classification","volume":"40","author":"Triposkiadis","year":"2019","journal-title":"Eur Heart J"},{"key":"R28-20250803","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/eurheartj\/ehaa587","article-title":"Assessing left ventricular systolic function: from ejection fraction to strain analysis","volume":"42","author":"Halliday","year":"2020","journal-title":"Eur Heart J"},{"key":"R29-20250803","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0735-1097(95)00153-Q","article-title":"Geometric changes allow normal ejection fraction despite depressed myocardial shortening in hypertensive left ventricular hypertrophy","volume":"26","author":"Aurigemma","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"R30-20250803","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.amjcard.2004.11.006","article-title":"Contribution of left ventricular diastolic dysfunction to heart failure regardless of ejection fraction","volume":"95","author":"Brucks","year":"2005","journal-title":"Am J Cardiol"},{"key":"R31-20250803","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1161\/CIRCULATIONAHA.116.025795","article-title":"Ejection fraction: misunderstood and overrated (changing the paradigm in categorizing heart failure)","volume":"135","author":"Konstam Marvin","year":"2017","journal-title":"Circulation"},{"key":"R32-20250803","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1161\/01.CIR.93.2.259","article-title":"Midwall left ventricular mechanics. An independent predictor of cardiovascular risk in arterial hypertension","volume":"93","author":"de Simone","year":"1996","journal-title":"Circulation"},{"key":"R33-20250803","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000021601.49664.2A","article-title":"Change in systolic left ventricular performance after 3\u200ayears of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study","volume":"106","author":"Wachtell","year":"2002","journal-title":"Circulation"},{"key":"R34-20250803","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0002-9149(00)01272-8","article-title":"Effect of electrocardiographic left ventricular hypertrophy on left ventricular systolic function in systemic hypertension (the LIFE study). Losartan Intervention For Endpoint","volume":"87","author":"Wachtell","year":"2001","journal-title":"Am J Cardiol"},{"key":"R35-20250803","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1097\/HJH.0000000000000432","article-title":"Relationship of left ventricular systolic function to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new heart failure","volume":"32","author":"Okin","year":"2014","journal-title":"J Hypertens"},{"key":"R36-20250803","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.jacc.2017.06.046","article-title":"Geometry as a confounder when assessing ventricular systolic function: comparison between ejection fraction and strain","volume":"70","author":"Stokke","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R37-20250803","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jcmg.2015.09.027","article-title":"Prognostic implications of lv strain risk score in asymptomatic patients with hypertensive heart disease","volume":"9","author":"Saito","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"key":"R38-20250803","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/ehjci\/jes026","article-title":"Correlates of global area strain in native hypertensive patients: a three-dimensional speckle-tracking echocardiography study","volume":"13","author":"Galderisi","year":"2012","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"R39-20250803","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1161\/CIRCULATIONAHA.115.015884","article-title":"Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone","volume":"132","author":"Shah","year":"2015","journal-title":"Circulation"},{"key":"R40-20250803","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/ejechocard\/jep052","article-title":"Right ventricular function in patients with preserved and reduced ejection fraction heart failure","volume":"10","author":"Puwanant","year":"2009","journal-title":"Eur J Echocardiogr"},{"key":"R41-20250803","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/ejhf.1029","article-title":"Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"Gorter","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"R42-20250803","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1093\/eurheartj\/ehy331","article-title":"Exercise unmasks distinct pathophysiologic features in heart failure with preserved ejection fraction and pulmonary vascular disease","volume":"39","author":"Gorter","year":"2018","journal-title":"Eur Heart J"},{"key":"R43-20250803","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jacc.2008.11.051","article-title":"Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study","volume":"53","author":"Lam","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R44-20250803","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/ehjci\/jex133","article-title":"Right ventricular-vascular coupling in heart failure with preserved ejection fraction and pre- vs. post-capillary pulmonary hypertension","volume":"19","author":"Gorter","year":"2018","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"R45-20250803","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/eurheartj\/ehy809","article-title":"Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction","volume":"40","author":"Obokata","year":"2019","journal-title":"Eur Heart J"},{"key":"R46-20250803","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1161\/01.CIR.0000048123.22359.A0","article-title":"Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications fo systolic and diastolic reserve limitations","volume":"107","author":"Kawaguchi","year":"2003","journal-title":"Circulation"},{"key":"R47-20250803","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/ejhf.1436","article-title":"The role of ventricular\u2013arterial coupling in cardiac disease and heart failure: assessment, clinical implications and therapeutic interventions. A consensus document of the European Society of Cardiology Working Group on Aorta & Peripheral Vascular Diseases, European Association of Cardiovascular Imaging, and Heart Failure Association","volume":"21","author":"Ikonomidis","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"R48-20250803","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1093\/eurheartj\/ehy346","article-title":"Pulsatile arterial haemodynamics in heart failure","volume":"39","author":"Weber","year":"2018","journal-title":"Eur Heart J"},{"key":"R49-20250803","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.hfc.2007.10.001","article-title":"Ventricular\u2013vascular interaction in heart failure","volume":"4","author":"Borlaug","year":"2008","journal-title":"Heart Fail Clin"},{"key":"R50-20250803","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jacc.2011.09.062","article-title":"Effects of vasodilation in heart failure with preserved or reduced ejection fraction: implications of distinct pathophysiologies on response to therapy","volume":"59","author":"Schwartzenberg","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R51-20250803","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1161\/CIRCULATIONAHA.106.632745","article-title":"Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction","volume":"114","author":"Borlaug Barry","year":"2006","journal-title":"Circulation"},{"key":"R52-20250803","doi-asserted-by":"crossref","first-page":"e006213","DOI":"10.1161\/CIRCHEARTFAILURE.119.006213","article-title":"Heart rate and heart failure with preserved ejection fraction: time to slow \u03b2-blocker use?","volume":"12","author":"Meyer","year":"2019","journal-title":"Circ Heart Fail"},{"key":"R53-20250803","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jacc.2019.05.052","article-title":"Age-related characteristics and outcomes of patients with heart failure with preserved ejection fraction","volume":"74","author":"Tromp","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R54-20250803","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jchf.2020.12.005","article-title":"The impact of patients with cardiac amyloidosis in HFpEF trials","volume":"9","author":"Oghina","year":"2021","journal-title":"JACC Heart Fail"},{"key":"R55-20250803","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/ejhf.1766","article-title":"The neglected issue of cardiac amyloidosis in trials on heart failure with preserved ejection fraction in the elderly","volume":"22","author":"Russo","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"R56-20250803","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1161\/CIRCHEARTFAILURE.113.000383","article-title":"Longitudinal changes in left ventricular stiffness: a community-based study","volume":"6","author":"Borlaug Barry","year":"2013","journal-title":"Circ Heart Fail"},{"key":"R57-20250803","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1161\/CIRCULATIONAHA.116.024825","article-title":"Contemporary assessment of left ventricular diastolic function in older adults: The Atherosclerosis Risk in Communities Study","volume":"135","author":"Shah","year":"2017","journal-title":"Circulation"},{"key":"R58-20250803","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1097\/HJH.0000000000002178","article-title":"Cross-sectional analysis of pulsatile hemodynamics across the adult life span: reference values, healthy and early vascular aging: the Heinz Nixdorf Recall and the MultiGeneration Study","volume":"37","author":"Weber","year":"2019","journal-title":"J Hypertens"},{"key":"R59-20250803","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1093\/eurheartj\/eht066","article-title":"Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND","volume":"34","author":"Brouwers","year":"2013","journal-title":"Eur Heart J"},{"key":"R60-20250803","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","article-title":"Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis","volume":"35","author":"Damman","year":"2014","journal-title":"Eur Heart J"},{"key":"R61-20250803","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/ejhf.461","article-title":"Renal dysfunction in heart failure with a preserved ejection fraction: cause or consequence?","volume":"18","author":"Ter Maaten","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"R62-20250803","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1681\/ASN.2012020145","article-title":"Associations between kidney function and subclinical cardiac abnormalities in CKD","volume":"23","author":"Park","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"R63-20250803","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/ejhf.445","article-title":"Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction","volume":"18","author":"Unger","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"R64-20250803","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1161\/CIRCULATIONAHA.117.028814","article-title":"Cardiorenal syndrome revisited","volume":"138","author":"Zannad","year":"2018","journal-title":"Circulation"},{"key":"R65-20250803","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"The Lancet"},{"key":"R66-20250803","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","article-title":"The perindopril in elderly people with chronic heart failure (PEP-CHF) study","volume":"27","author":"Cleland","year":"2006","journal-title":"Eur Heart J"},{"key":"R67-20250803","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"key":"R68-20250803","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"R69-20250803","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"R70-20250803","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.amjcard.2020.01.009","article-title":"Meta-analysis evaluating the effects of renin-angiotensin-aldosterone system blockade on outcomes of heart failure with preserved ejection fraction","volume":"125","author":"Kuno","year":"2020","journal-title":"Am J Cardiol"},{"key":"R71-20250803","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.amjcard.2021.01.013","article-title":"Meta-analysis of efficacy of sacubitril\/valsartan in heart failure with preserved ejection fraction","volume":"145","author":"Salah","year":"2021","journal-title":"Am J Cardiol"},{"key":"R72-20250803","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/01.CIR.0000141573.44737.5A","article-title":"Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial","volume":"110","author":"Devereux Richard","year":"2004","journal-title":"Circulation"},{"key":"R73-20250803","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1001\/jama.2012.14785","article-title":"Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction","volume":"308","author":"Lund","year":"2012","journal-title":"JAMA"},{"key":"R74-20250803","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/ehf2.12204","article-title":"Renin\u2013angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"4","author":"Khan","year":"2017","journal-title":"ESC Heart Fail"},{"key":"R75-20250803","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/ejhf.1060","article-title":"Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial","volume":"20","author":"Selvaraj","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"R76-20250803","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.jacc.2020.02.009","article-title":"Systolic blood pressure in heart failure with preserved ejection fraction treated with sacubitril\/valsartan","volume":"75","author":"Selvaraj","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R77-20250803","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/ajh.2010.105","article-title":"Ethnic differences in blood pressure response to first and second-line antihypertensive therapies in patients randomized in the ASCOT trial","volume":"23","author":"Gupta","year":"2010","journal-title":"Am J Hypertens"},{"key":"R78-20250803","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jacc.2015.07.021","article-title":"Comparative effectiveness of angiotensin-converting enzyme inhibitor-based treatment on cardiovascular outcomes in hypertensive blacks versus whites","volume":"66","author":"Ogedegbe","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"R79-20250803","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/0735-1097(94)90385-9","article-title":"Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the registry of studies of left ventricular dysfunction. SOLVD Investigators","volume":"23","author":"Benedict","year":"1994","journal-title":"J Am Coll Cardiol"},{"key":"R80-20250803","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijcard.2019.08.040","article-title":"Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved, mid-range and reduced ejection fraction","volume":"296","author":"Vergaro","year":"2019","journal-title":"Int J Cardiol"},{"key":"R81-20250803","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1161\/HYPERTENSIONAHA.115.05285","article-title":"Plasma aldosterone and left ventricular diastolic function in treatment-na\u00efve patients with hypertension: tissue-doppler imaging study","volume":"65","author":"Catena","year":"2015","journal-title":"Hypertension"},{"key":"R82-20250803","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijcard.2020.05.084","article-title":"Blockade of the neurohormonal systems in heart failure with preserved ejection fraction: a contemporary meta-analysis","volume":"316","author":"Gallo","year":"2020","journal-title":"Int J Cardiol"},{"key":"R83-20250803","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/14779072.7.1.9","article-title":"The CHARM program: the effects of candesartan for the management of patients with chronic heart failure","volume":"7","author":"McKelvie","year":"2009","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"R84-20250803","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/ejhf.29","article-title":"Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved","volume":"16","author":"Rogers","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"R85-20250803","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/ejhf.1149","article-title":"Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum","volume":"20","author":"Lund","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"R86-20250803","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1007\/s00392-020-01632-x","article-title":"Covariate adjusted reanalysis of the I-Preserve trial","volume":"109","author":"Ferreira","year":"2020","journal-title":"Clin Res Cardiol"},{"key":"R87-20250803","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jchf.2017.04.013","article-title":"Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial","volume":"5","author":"Solomon","year":"2017","journal-title":"JACC Heart Fail"},{"key":"R88-20250803","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jacc.2020.05.072","article-title":"Effect of sacubitril\/valsartan on biomarkers of extracellular matrix regulation in patients with HFpEF","volume":"76","author":"Cunningham","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R89-20250803","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jchf.2019.07.005","article-title":"Circulating neprilysin in patients with heart failure and preserved ejection fraction","volume":"8","author":"Lyle","year":"2020","journal-title":"JACC Heart Fail"},{"key":"R90-20250803","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","article-title":"Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study","volume":"375","author":"Ruilope","year":"2010","journal-title":"Lancet"},{"key":"R91-20250803","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1093\/eurheartj\/ehx525","article-title":"The effect of sacubitril\/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study","volume":"38","author":"Schmieder","year":"2017","journal-title":"Eur Heart J"},{"key":"R92-20250803","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"R93-20250803","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"Prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction (PARAMOUNT) investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"R95-20250803","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.119.044491","article-title":"Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF","volume":"141","author":"McMurray John","year":"2020","journal-title":"Circulation"},{"key":"R96-20250803","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure","volume":"141","author":"Solomon Scott","year":"2020","journal-title":"Circulation"},{"key":"R97-20250803","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jacc.2019.11.003","article-title":"Prior heart failure hospitalization, clinical outcomes, and response to sacubitril\/valsartan compared with valsartan in HFpEF","volume":"75","author":"Vaduganathan","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R98-20250803","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1161\/CIRCULATIONAHA.120.047643","article-title":"Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction","volume":"142","author":"Mc Causland Finnian","year":"2020","journal-title":"Circulation"},{"key":"R99-20250803","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jchf.2020.08.014","article-title":"Cardiovascular and renal outcomes of mineralocorticoid receptor antagonist use in PARAGON-HF","volume":"9","author":"Jering","year":"2020","journal-title":"JACC Heart Fail"},{"key":"R100-20250803","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1093\/eurheartj\/ehaa184","article-title":"A putative placebo analysis of the effects of sacubitril\/valsartan in heart failure across the full range of ejection fraction","volume":"41","author":"Vaduganathan","year":"2020","journal-title":"Eur Heart J"},{"key":"R101-20250803","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/ehf2.12694","article-title":"Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial","volume":"7","author":"Wachter","year":"2020","journal-title":"ESC Heart Fail"},{"key":"R102-20250803","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1093\/eurheartj\/ehaa797","article-title":"Late-breaking clinical trials - ESC Congress 2020","volume":"41","author":"Nicholls","year":"2020","journal-title":"Eur Heart J"},{"key":"R103-20250803","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","article-title":"Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators","volume":"102","author":"Zannad","year":"2000","journal-title":"Circulation"},{"key":"R104-20250803","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0735-1097(01)01729-6","article-title":"Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression","volume":"39","author":"Bauersachs","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R105-20250803","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jacc.2009.03.066","article-title":"Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial","volume":"54","author":"Edwards","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R106-20250803","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"key":"R107-20250803","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer Marc","year":"2015","journal-title":"Circulation"},{"key":"R108-20250803","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMc1612601","article-title":"Spironolactone metabolites in TOPCAT \u2014 new insights into regional variation","volume":"376","author":"de Denus","year":"2017","journal-title":"N Engl J Med"},{"key":"R109-20250803","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/ejhf.621","article-title":"A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis","volume":"18","author":"Girerd","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"R110-20250803","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction","volume":"37","author":"Solomon","year":"2016","journal-title":"Eur Heart J"},{"key":"R111-20250803","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ejhf.85","article-title":"Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve)","volume":"16","author":"B\u00f6hm","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"R112-20250803","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/S0735-1097(98)00478-1","article-title":"Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study","volume":"32","author":"Luchner","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"R113-20250803","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1161\/HYPERTENSIONAHA.115.06467","article-title":"Effects of \u03b2-blockers with and without vasodilating properties on central blood pressure: systematic review and meta-analysis of randomized trials in hypertension","volume":"67","author":"Pucci","year":"2016","journal-title":"Hypertension"},{"key":"R114-20250803","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jacc.2008.09.031","article-title":"Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) registry","volume":"53","author":"Hernandez","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R115-20250803","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/eurjhf\/hfs141","article-title":"Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF)","volume":"15","author":"Yamamoto","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"R116-20250803","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10741-014-9453-8","article-title":"Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis","volume":"20","author":"Bavishi","year":"2015","journal-title":"Heart Fail Rev"},{"key":"R117-20250803","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"key":"R118-20250803","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/eurjhf\/hfr161","article-title":"Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study","volume":"14","author":"Conraads","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"R119-20250803","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/ejhf.876","article-title":"Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial","volume":"19","author":"Komajda","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"R120-20250803","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland","year":"2018","journal-title":"Eur Heart J"},{"key":"R121-20250803","doi-asserted-by":"crossref","first-page":"e1916598","DOI":"10.1001\/jamanetworkopen.2019.16598","article-title":"Association of (-blocker use with heart failure hospitalizations and cardiovascular disease mortality among patients with heart failure with a preserved ejection fraction: a secondary analysis of the TOPCAT trial","volume":"2","author":"Silverman","year":"2019","journal-title":"JAMA Netw Open"},{"key":"R122-20250803","doi-asserted-by":"crossref","first-page":"e013389","DOI":"10.1161\/JAHA.119.013389","article-title":"SGLT-2 inhibitors in heart failure: current management, unmet needs, and therapeutic prospects","volume":"8","author":"Lam","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"R123-20250803","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2337\/dci19-0066","article-title":"2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"43","author":"Buse","year":"2020","journal-title":"Diabetes Care"},{"key":"R124-20250803","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2213-8587(20)30343-0","article-title":"Guideline recommendations and the positioning of newer drugs in type 2 diabetes care","volume":"9","author":"Marx","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R125-20250803","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.amjcard.2003.12.026","article-title":"Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus","volume":"93","author":"Boyer","year":"2004","journal-title":"Am J Cardiol"},{"key":"R126-20250803","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s00125-010-1718-8","article-title":"Association of glucose metabolism with diastolic function along the diabetic continuum","volume":"53","author":"Stahrenberg","year":"2010","journal-title":"Diabetologia"},{"key":"R127-20250803","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.amjcard.2009.09.041","article-title":"Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus","volume":"105","author":"Aguilar","year":"2010","journal-title":"Am J Cardiol"},{"key":"R128-20250803","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"R129-20250803","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/cvr\/cvy295","article-title":"Potential mechanisms underlying the cardiovascular benefits of sodium glucose cotransporter 2 inhibitors: a systematic review of data from preclinical studies","volume":"115","author":"Chin","year":"2019","journal-title":"Cardiovasc Res"},{"key":"R130-20250803","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/dom.13126","article-title":"Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis","volume":"20","author":"Hallow","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"R131-20250803","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1161\/CIRCULATIONAHA.117.029529","article-title":"Effects of the selective sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function and central hemodynamics in patients with type 2 diabetes mellitus","volume":"136","author":"Striepe","year":"2017","journal-title":"Circulation"},{"key":"R132-20250803","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"key":"R133-20250803","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/ejhf.1328","article-title":"Empagliflozin directly improves diastolic function in human heart failure","volume":"20","author":"Pabel","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"R134-20250803","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jacbts.2018.07.006","article-title":"Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors","volume":"3","author":"Verma","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"R135-20250803","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"R136-20250803","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"R137-20250803","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"R138-20250803","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"R139-20250803","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"R140-20250803","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"R141-20250803","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"R142-20250803","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/ejhf.1673","article-title":"European Society of Cardiology\/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure","volume":"22","author":"Seferovi\u0107","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"R143-20250803","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/ejhf.1954","article-title":"Sodium\u2013glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology","volume":"22","author":"Seferovi\u0107","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"R144-20250803","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/ejhf.2026","article-title":"Heart Failure Association of the European Society of Cardiology update on sodium\u2013glucose co-transporter 2 inhibitors in heart failure","volume":"22","author":"Seferovi\u0107","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"R145-20250803","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/ejhf.1419","article-title":"Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline","volume":"21","author":"Januzzi","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"R146-20250803","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2020","journal-title":"N Engl J Med"},{"key":"R147-20250803","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/eurheartj\/ehab136","article-title":"The value of sotagliflozin in patients with diabetes and heart failure detracted by an unexpected ending","volume":"42","author":"Volpe","year":"2021","journal-title":"Eur Heart J"},{"key":"R148-20250803","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00392-017-1170-6","article-title":"Heart failure with preserved ejection fraction: current management and future strategies: expert opinion on the behalf of the Nucleus of the \u201cHeart Failure Working Group\u201d of the German Society of Cardiology (DKG)","volume":"107","author":"Tsch\u00f6pe","year":"2018","journal-title":"Clin Res Cardiol"},{"key":"R149-20250803","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00392-020-01633-w","article-title":"Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future","volume":"109","author":"Wintrich","year":"2020","journal-title":"Clin Res Cardiol"},{"key":"R150-20250803","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jama.2013.2024","article-title":"Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial","volume":"309","author":"Redfield","year":"2013","journal-title":"JAMA"},{"key":"R151-20250803","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/jamacardio.2018.2936","article-title":"One-year safety and clinical outcomes of a transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) trial: a randomized clinical trial","volume":"3","author":"Shah","year":"2018","journal-title":"JAMA Cardiol"},{"key":"R152-20250803","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/HJH.0000000000000408","article-title":"Effects of multielectrode renal denervation on cardiac and neurohumoral adaptations in resistant hypertension with cardiac hypertrophy: an EnligHTN I substudy","volume":"33","author":"Tsioufis","year":"2015","journal-title":"J Hypertens"},{"key":"R153-20250803","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/S0140-6736(18)30951-6","article-title":"Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial","volume":"391","author":"Kandzari","year":"2018","journal-title":"Lancet"},{"key":"R154-20250803","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/S0140-6736(20)30554-7","article-title":"Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial","volume":"395","author":"B\u00f6hm","year":"2020","journal-title":"Lancet"},{"key":"R155-20250803","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/ejhf.502","article-title":"Renal denervation in heart failure with preserved ejection fraction (RDT-PEF): a randomized controlled trial","volume":"18","author":"Patel","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"R156-20250803","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jacc.2011.11.040","article-title":"Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction","volume":"59","author":"Ather","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R157-20250803","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1111\/jch.14004","article-title":"Hypertension, heart failure, and frailty in older people: a common but unclear situation","volume":"22","author":"Camafort","year":"2020","journal-title":"J Clin Hypertens"},{"key":"R158-20250803","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1097\/00004872-199609002-00018","article-title":"Regression of left ventricular hypertrophy as a surrogate end-point for morbid events in hypertension treatment trials","volume":"14","author":"Devereux","year":"1996","journal-title":"J Hypertens"},{"key":"R159-20250803","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1161\/HYPERTENSIONAHA.109.136655","article-title":"Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies","volume":"54","author":"Fagard Robert","year":"2009","journal-title":"Hypertension"},{"key":"R160-20250803","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.2174\/1381612825666181203092918","article-title":"Treatment of hypertensive left ventricular hypertrophy","volume":"24","author":"Jekell","year":"2018","journal-title":"Curr Pharm Design"},{"key":"R161-20250803","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.phrs.2018.06.026","article-title":"Changes in left ventricular geometry during antihypertensive treatment","volume":"134","author":"Salvetti","year":"2018","journal-title":"Pharmacol Res"},{"key":"R162-20250803","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1161\/hc0902.104599","article-title":"Change in diastolic left ventricular filling after one year of antihypertensive treatment: the losartan intervention for endpoint reduction in hypertension (LIFE) study","volume":"105","author":"Wachtell","year":"2002","journal-title":"Circulation"},{"key":"R163-20250803","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1001\/jama.292.19.2343","article-title":"Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events","volume":"292","author":"Okin","year":"2004","journal-title":"JAMA"},{"key":"R164-20250803","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41440-019-0216-8","article-title":"Effects of blood pressure lowering in patients with heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"42","author":"Kawano","year":"2019","journal-title":"Hypertens Res"},{"key":"R165-20250803","doi-asserted-by":"crossref","first-page":"e003613","DOI":"10.1161\/CIRCHEARTFAILURE.116.003613","article-title":"Effect of intensive blood pressure treatment on heart failure events in the systolic blood pressure reduction intervention trial","volume":"10","author":"Upadhya","year":"2017","journal-title":"Circ Heart Fail"},{"key":"R166-20250803","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1001\/jama.1997.03550030052033","article-title":"Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group","volume":"278","author":"Kostis","year":"1997","journal-title":"JAMA"},{"key":"R167-20250803","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/HJH.0000000000000848","article-title":"Effects of blood pressure-lowering treatment. 6. Prevention of heart failure and new-onset heart failure \u2013 meta-analyses of randomized trials","volume":"34","author":"Thomopoulos","year":"2016","journal-title":"J Hypertens"},{"key":"R169-20250803","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/ajh\/hpx210","article-title":"Spironolactone and resistant hypertension in heart failure with preserved ejection fraction","volume":"31","author":"Rossignol","year":"2018","journal-title":"Am J Hypertens"},{"key":"R170-20250803","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1016\/j.amjmed.2020.08.030","article-title":"Systolic blood pressure and outcomes in older patients with HFpEF and hypertension","volume":"134","author":"Faselis","year":"2021","journal-title":"Am J Med"},{"key":"R171-20250803","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jamacardio.2017.5365","article-title":"Systolic blood pressure and outcomes in patients with heart failure with preserved ejection fraction","volume":"3","author":"Tsimploulis","year":"2018","journal-title":"JAMA Cardiol"},{"key":"R172-20250803","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1253\/circj.CJ-16-0740","article-title":"Riser pattern is a novel predictor of adverse events in heart failure patients with preserved ejection fraction","volume":"81","author":"Komori","year":"2017","journal-title":"Circ J"},{"key":"R173-20250803","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/ehf2.12500","article-title":"Differences in blood pressure riser pattern in patients with acute heart failure with reduced mid-range and preserved ejection fraction","volume":"6","author":"Ueda","year":"2019","journal-title":"ESC Heart Fail"},{"key":"R174-20250803","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jchf.2017.08.015","article-title":"Reverse j-curve relationship between on-treatment blood pressure and mortality in patients with heart failure","volume":"5","author":"Lee","year":"2017","journal-title":"JACC Heart Fail"},{"key":"R175-20250803","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s10741-018-09766-x","article-title":"Obesity and heart failure with preserved ejection fraction: a paradox or something else?","volume":"24","author":"Tadic","year":"2019","journal-title":"Heart Fail Rev"},{"key":"R176-20250803","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"R177-20250803","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/jama.2015.17346","article-title":"Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial","volume":"315","author":"Kitzman","year":"2016","journal-title":"JAMA"},{"key":"R178-20250803","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.amjmed.2019.07.034","article-title":"Salt, no salt, or less salt for patients with heart failure?","volume":"133","author":"Khan","year":"2020","journal-title":"Am J Med"},{"key":"R179-20250803","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1161\/CIRCHEARTFAILURE.113.000481","article-title":"Low-sodium dash diet improves diastolic function and ventricular\u2013arterial coupling in hypertensive heart failure with preserved ejection fraction","volume":"6","author":"Hummel Scott","year":"2013","journal-title":"Circ Heart Fail"},{"key":"R180-20250803","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/j.jacc.2011.06.054","article-title":"Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study","volume":"58","author":"Edelmann","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"R181-20250803","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1161\/CIRCULATIONAHA.117.028002","article-title":"Physical activity and prognosis in the TOPCAT trial (treatment of preserved cardiac function heart failure with an aldosterone antagonist)","volume":"136","author":"Hegde Sheila","year":"2017","journal-title":"Circulation"},{"key":"R182-20250803","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10741-019-09774-5","article-title":"Effects of exercise training on cardiac function, exercise capacity, and quality of life in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials","volume":"24","author":"Fukuta","year":"2019","journal-title":"Heart Fail Rev"},{"key":"R183-20250803","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1001\/jama.2020.26812","article-title":"Effect of high-intensity interval training, moderate continuous training, or guideline-based physical activity advice on peak oxygen consumption in patients with heart failure with preserved ejection fraction: a randomized clinical trial","volume":"325","author":"Mueller","year":"2021","journal-title":"JAMA"},{"key":"R184-20250803","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/eurheartj\/ehaa605","article-title":"2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease: the Task Force on sports cardiology and exercise in patients with cardiovascular disease of the European Society of Cardiology (ESC)","volume":"42","author":"Pelliccia","year":"2021","journal-title":"Eur Heart J"},{"key":"R185-20250803","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwaa091","article-title":"Combined aerobic\/resistance\/inspiratory muscle training as the \u2018optimum\u2019 exercise programme for patients with chronic heart failure: ARISTOS-HF randomized clinical trial","author":"Laoutaris","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"R186-20250803","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/S0735-1097(99)00048-0","article-title":"Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise","volume":"33","author":"Warner James","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"R187-20250803","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1016\/S0140-6736(07)60980-5","article-title":"Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial","volume":"369","author":"Solomon","year":"2007","journal-title":"Lancet"},{"key":"R188-20250803","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jacc.2020.06.022","article-title":"Loop diuretic prescription and 30-day outcomes in older patients with heart failure","volume":"76","author":"Faselis","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R189-20250803","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ejhf.1369","article-title":"The use of diuretics in heart failure with congestion: a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Mullens","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"R190-20250803","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jchf.2015.11.011","article-title":"Interventions linked to decreased heart failure hospitalizations during ambulatory pulmonary artery pressure monitoring","volume":"4","author":"Costanzo","year":"2016","journal-title":"JACC Heart Fail"},{"key":"R191-20250803","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1161\/CIRCHEARTFAILURE.113.001229","article-title":"Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction","volume":"7","author":"Adamson Philip","year":"2014","journal-title":"Circ Heart Fail"},{"key":"R192-20250803","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1161\/HYPERTENSIONAHA.108.125278","article-title":"Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure","volume":"53","author":"L\u00f3pez","year":"2009","journal-title":"Hypertension"},{"key":"R195-20250803","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/ejhf.1194","article-title":"Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial","volume":"20","author":"Ravassa","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"R196-20250803","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/eurheartj\/ehaa758","article-title":"The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart \u2018OMics\u2019 in AGEing (HOMAGE) randomized clinical trial","volume":"42","author":"Cleland","year":"2020","journal-title":"Eur Heart J"},{"key":"R197-20250803","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1097\/HJH.0b013e3282170ada","article-title":"Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA)","volume":"25","author":"M\u00fcller-Brunotte","year":"2007","journal-title":"J Hypertens"},{"key":"R198-20250803","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1161\/HYPERTENSIONAHA.109.149112","article-title":"Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction","volume":"55","author":"Gonz\u00e1lez","year":"2010","journal-title":"Hypertension"},{"key":"R199-20250803","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1161\/HYPERTENSIONAHA.120.16277","article-title":"Pulse pressure, prognosis, and influence of sacubitril\/valsartan in heart failure with preserved ejection fraction","volume":"77","author":"Suzuki","year":"2021","journal-title":"Hypertension"},{"key":"R202-20250803","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/0002-9149(90)90937-V","article-title":"Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance","volume":"66","author":"Setaro","year":"1990","journal-title":"Am J Cardiol"},{"key":"R203-20250803","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jchf.2013.04.004","article-title":"Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2)","volume":"1","author":"Packer","year":"2013","journal-title":"JACC Heart Fail"},{"key":"R204-20250803","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1161\/CIRCHEARTFAILURE.114.001301","article-title":"Calcium channel blockers and outcomes in older patients with heart failure and preserved ejection fraction","volume":"7","author":"Patel","year":"2014","journal-title":"Circ Heart Fail"},{"key":"R205-20250803","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1097\/HJH.0000000000002523","article-title":"Beta-blockers in hypertension: overview and meta-analysis of randomized outcome trials","volume":"38","author":"Thomopoulos","year":"2020","journal-title":"J Hypertens"},{"key":"R207-20250803","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1001\/jamacardio.2017.2511","article-title":"Temporal relation between myocardial fibrosis and heart failure with preserved ejection fraction: association with baseline disease severity and subsequent outcome","volume":"2","author":"Schelbert","year":"2017","journal-title":"JAMA Cardiol"},{"key":"R208-20250803","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1161\/01.CIR.0000017264.66561.3D","article-title":"losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients","volume":"105","author":"D\u00edez","year":"2002","journal-title":"Circulation"},{"key":"R209-20250803","doi-asserted-by":"crossref","first-page":"e011521","DOI":"10.1161\/JAHA.118.011521","article-title":"Myocardial effects of aldosterone antagonism in heart failure with preserved ejection fraction","volume":"9","author":"McDiarmid Adam","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"R210-20250803","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jacc.2020.07.009","article-title":"Atrial dysfunction in patients with heart failure with preserved ejection fraction and atrial fibrillation","volume":"76","author":"Reddy","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R211-20250803","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s12265-017-9739-z","article-title":"Phenomapping for the identification of hypertensive patients with the myocardial substrate for heart failure with preserved ejection fraction","volume":"10","author":"Katz","year":"2017","journal-title":"J Cardiovasc Transl Res"},{"key":"R212-20250803","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1093\/eurheartj\/ehv529","article-title":"Myocardial strain imaging: how useful is it in clinical decision making?","volume":"37","author":"Smiseth","year":"2016","journal-title":"Eur Heart J"},{"key":"R213-20250803","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1161\/HYPERTENSIONAHA.116.08545","article-title":"Reduced first-phase ejection fraction and sustained myocardial wall stress in hypertensive patients with diastolic dysfunction: a manifestation of impaired shortening deactivation that links systolic to diastolic dysfunction and preserves systolic ejection fraction","volume":"69","author":"Gu","year":"2017","journal-title":"Hypertension"},{"key":"R214-20250803","first-page":"0","article-title":"The conceptual basis for a Universal Definition of Heart Failure: congestion due to cardiac dysfunction","author":"Cleland John","year":"2021","journal-title":"Eur Heart J"},{"key":"R215-20250803","first-page":"1","article-title":"The struggle towards a Universal Definition of Heart Failure: how to proceed?","volume":"0","author":"Bauersachs","year":"2021","journal-title":"Eur Heart J"},{"key":"R216-20250803","first-page":"1","article-title":"Counter point: no evidence for the proposed Universal Definition of Heart Failure","volume":"0","author":"Pfeffer Marc","year":"2021","journal-title":"Eur Heart J"},{"key":"R217-20250803","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.jchf.2020.10.002","article-title":"Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium","volume":"8","author":"Abraham","year":"2020","journal-title":"JACC Heart Fail"},{"key":"R218-20250803","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/CIRCHEARTFAILURE.111.962654","article-title":"Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial","volume":"4","author":"Anand Inder","year":"2011","journal-title":"Circ Heart Fail"},{"key":"R219-20250803","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jchf.2016.11.015","article-title":"Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT Trial","volume":"5","author":"Anand","year":"2017","journal-title":"JACC Heart Fail"},{"key":"R220-20250803","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jchf.2020.03.002","article-title":"Effects of sacubitril\/valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in heart failure with preserved ejection fraction","volume":"8","author":"Cunningham","year":"2020","journal-title":"JACC Heart Fail"}],"container-title":["Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HJH.0000000000002910","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T21:25:23Z","timestamp":1754256323000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/HJH.0000000000002910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,16]]},"references-count":213,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/hjh.0000000000002910","relation":{},"ISSN":["0263-6352","1473-5598"],"issn-type":[{"value":"0263-6352","type":"print"},{"value":"1473-5598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,16]]}}}